Insecticides India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 10, 2025, 9:14 pm

Competitors of Insecticides India Ltd

All Competitor Stocks of Insecticides India Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:00 am

Below is a detailed analysis of the quarterly data for Insecticides India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 691.00 Cr.. The value appears strong and on an upward trend. It has increased from 359.00 Cr. (Mar 2025) to 691.00 Cr., marking an increase of 332.00 Cr..
• For Expenses, as of Jun 2025, the value is 607.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 331.00 Cr. (Mar 2025) to 607.00 Cr., marking an increase of 276.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 56.00 Cr..
• For OPM %, as of Jun 2025, the value is 12.00%. The value appears strong and on an upward trend. It has increased from 8.00% (Mar 2025) to 12.00%, marking an increase of 4.00%.
• For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 77.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 55.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 37.00% (Mar 2025) to 25.00%, marking a decrease of 12.00%.
• For Net Profit, as of Jun 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 43.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 19.36. The value appears strong and on an upward trend. It has increased from 4.74 (Mar 2025) to 19.36, marking an increase of 14.62.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:07 am

Growth

Last Updated: September 5, 2025, 7:40 am

Balance Sheet

Last Updated: July 25, 2025, 3:00 pm

Below is a detailed analysis of the balance sheet data for Insecticides India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 29.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Mar 2024) to 29.00 Cr., marking a decrease of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,053.00 Cr.. The value appears strong and on an upward trend. It has increased from 982.00 Cr. (Mar 2024) to 1,053.00 Cr., marking an increase of 71.00 Cr..
• For Borrowings, as of Mar 2025, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 87.00 Cr. (Mar 2024) to 104.00 Cr., marking an increase of 17.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 702.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 611.00 Cr. (Mar 2024) to 702.00 Cr., marking an increase of 91.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,888.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,710.00 Cr. (Mar 2024) to 1,888.00 Cr., marking an increase of 178.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 278.00 Cr.. The value appears to be declining and may need further review. It has decreased from 283.00 Cr. (Mar 2024) to 278.00 Cr., marking a decrease of 5.00 Cr..
• For CWIP, as of Mar 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 141.00 Cr. (Mar 2024) to 161.00 Cr., marking an increase of 20.00 Cr..
• For Investments, as of Mar 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2024) to 26.00 Cr., marking an increase of 7.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,267.00 Cr. (Mar 2024) to 1,422.00 Cr., marking an increase of 155.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,888.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,710.00 Cr. (Mar 2024) to 1,888.00 Cr., marking an increase of 178.00 Cr..

Notably, the Reserves (1,053.00 Cr.) exceed the Borrowings (104.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Insecticides India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 48.38. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.38, marking an increase of 13.79.
• For Diluted EPS (Rs.), as of Mar 25, the value is 48.38. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.38, marking an increase of 13.79.
• For Cash EPS (Rs.), as of Mar 25, the value is 58.63. This value is within the healthy range. It has increased from 44.36 (Mar 24) to 58.63, marking an increase of 14.27.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 372.74. It has increased from 342.44 (Mar 24) to 372.74, marking an increase of 30.30.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 372.74. It has increased from 342.44 (Mar 24) to 372.74, marking an increase of 30.30.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 687.32. It has increased from 664.37 (Mar 24) to 687.32, marking an increase of 22.95.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 78.43. This value is within the healthy range. It has increased from 58.12 (Mar 24) to 78.43, marking an increase of 20.31.
• For PBIT / Share (Rs.), as of Mar 25, the value is 68.41. This value is within the healthy range. It has increased from 48.24 (Mar 24) to 68.41, marking an increase of 20.17.
• For PBT / Share (Rs.), as of Mar 25, the value is 66.05. This value is within the healthy range. It has increased from 44.56 (Mar 24) to 66.05, marking an increase of 21.49.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 48.61. This value is within the healthy range. It has increased from 34.48 (Mar 24) to 48.61, marking an increase of 14.13.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.81. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.81, marking an increase of 14.22.
• For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 8.74 (Mar 24) to 11.41, marking an increase of 2.67.
• For PBIT Margin (%), as of Mar 25, the value is 9.95. This value is below the healthy minimum of 10. It has increased from 7.26 (Mar 24) to 9.95, marking an increase of 2.69.
• For PBT Margin (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 10. It has increased from 6.70 (Mar 24) to 9.60, marking an increase of 2.90.
• For Net Profit Margin (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has increased from 5.18 (Mar 24) to 7.07, marking an increase of 1.89.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.10. This value is below the healthy minimum of 8. It has increased from 5.20 (Mar 24) to 7.10, marking an increase of 1.90.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.09. This value is below the healthy minimum of 15. It has increased from 10.09 (Mar 24) to 13.09, marking an increase of 3.00.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.76. This value is within the healthy range. It has increased from 13.50 (Mar 24) to 17.76, marking an increase of 4.26.
• For Return On Assets (%), as of Mar 25, the value is 7.48. This value is within the healthy range. It has increased from 5.97 (Mar 24) to 7.48, marking an increase of 1.51.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has decreased from 1.15 (Mar 24) to 1.11, marking a decrease of 0.04.
• For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.83, marking a decrease of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.69, marking an increase of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 4. It has increased from 1.60 (Mar 24) to 2.36, marking an increase of 0.76.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.16. This value is below the healthy minimum of 20. It has decreased from 8.67 (Mar 24) to 4.16, marking a decrease of 4.51.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 20. It has decreased from 6.74 (Mar 24) to 3.45, marking a decrease of 3.29.
• For Earning Retention Ratio (%), as of Mar 25, the value is 95.84. This value exceeds the healthy maximum of 70. It has increased from 91.33 (Mar 24) to 95.84, marking an increase of 4.51.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.55. This value exceeds the healthy maximum of 70. It has increased from 93.26 (Mar 24) to 96.55, marking an increase of 3.29.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 33.25. This value is within the healthy range. It has increased from 15.80 (Mar 24) to 33.25, marking an increase of 17.45.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.61. This value is within the healthy range. It has increased from 10.37 (Mar 24) to 21.61, marking an increase of 11.24.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,764.96. It has increased from 1,468.53 (Mar 24) to 1,764.96, marking an increase of 296.43.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has increased from 0.74 (Mar 24) to 0.88, marking an increase of 0.14.
• For EV / EBITDA (X), as of Mar 25, the value is 7.73. This value is within the healthy range. It has decreased from 8.54 (Mar 24) to 7.73, marking a decrease of 0.81.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 24) to 0.86, marking an increase of 0.13.
• For Retention Ratios (%), as of Mar 25, the value is 95.83. This value exceeds the healthy maximum of 70. It has increased from 91.32 (Mar 24) to 95.83, marking an increase of 4.51.
• For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has increased from 1.43 (Mar 24) to 1.59, marking an increase of 0.16.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 24) to 0.86, marking an increase of 0.13.
• For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 24) to 0.08, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness